

Legacy Day Treatment Unit Provider's Orders

Adult Ambulatory Infusion Order DENOSUMAB (Xgeva)

Patient Name:	
Date of Birth:	
Med. Rec. No (TVC MRN Only):	

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

This	pated Start Date: Patient to follow up with provider on date: plan will expire after 365 days, unless otherwise specified below s expire:
Weigh	nt:kg Height:cm
Allerg	ies:
Diagn	osis: Diagnosis Code:
GUIDE	ELINES FOR PRESCRIBING:
2. 3. 4. 5. 6. 7.	Send FACE SHEET, INSURANCE CARD and most recent provider chart or progress note. Please confirm that patient has had a recent oral examination prior to initiating therapy. Schedule for a dental exam if indicated – dental clearance form on page 3, if needed Risk versus benefit regarding osteonecrosis of the jaw and hip fracture must be discussed prior to treatment Hypocalcemia must be corrected before initiation of therapy All patients should be prescribed daily calcium and vitamin D supplementation a. Recommended dosing: calcium 1200 mg and vitamin D 400 IU-800 IU daily Quarterly monitoring of calcium, magnesium, and phosphorous is recommended during treatment CMP must be within 7 days of treatment for every 4 weeks dosing or within 30 days of treatment for every 12 weeks dosing, unless otherwise specified: TO BE DRAWN (orders must be placed in TVC Epic by ordering provider if TVC provider): CMP, Routine, every visit prior to Xgeva dose
DENT	AL CLEARANCE: (Must select one)
	Dental clearance required prior to initiation (form on page 3) – Recommended , not required Patient may be treated without documentation of dental clearance
MEDIC	CATIONS:
•	denosumab (Xgeva) 120 mg (1.7 mL) SUBCUTANEOUSLY, every visit. Administer injection into upper arm, upper thigh, or abdomen
FREQ	UENCY:
	Every 4 weeks Every 12 weeks Other

Page 1 of 3 Last updated 6/2024



Legacy Day Treatment Unit Provider's Orders

Adult Ambulatory Infusion Order DENOSUMAB (Xgeva)

Patient Name:	
Date of Birth:	
Med. Rec. No (TVC MRN Only):	

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

NURSING ORDERS (TREATMENT PARAMETERS):

- 1. Nursing order, ONCE: Review previous serum creatinine (SCr) and serum calcium
- 2. Treatment parameters, ONCE: Hold and notify MD for corrected calcium less than 8.4.
- 3. Nursing communication order, every visit: If corrected calcium is between 8.4 and 8.8 or creatinine clearance <30 mL/min review home medication for calcium and vitamin D supplementation. If patient is not on these agents, notify provider
- 4. Assess for jaw pain. Inform provider if positive findings or if patient is anticipating invasive dental work
- 5. Nursing communication orders, every visit: Manage hypersensitivity reactions per LH 906.6606

Please check the appropriate box for the patient's preferred clinic location: □ Legacy Day Treatment Unit – ☐ Legacy Emanuel Day Treatment Unit The Vancouver Clinic Building A department of Emanuel Medical Center A department of Salmon Creek Medical Center 501 N Graham Street, Suite 540 700 NE 87th Avenue, Suite 360 Portland, OR 97227 Vancouver, WA 98664 Phone number: 503-413-4608 Phone number: 360-896-7070 Fax number: 503-413-4887 Fax number: 360-487-5773 ☐ Legacy STEPS Clinic ☐ Legacy Salmon Creek Day Treatment Unit Legacy Salmon Creek Medical Center A department of Silverton Medical Center 2121 NE 139th Street, Suite 110 Legacy Woodburn Health Center Vancouver, WA 98686 1475 Mt Hood Ave Phone number: 360-487-1750 Woodburn, OR 97071 Fax number: 360-487-5773 Phone number: 503-982-1280 Fax number: 503-225-8723 Date/Time: _____ Provider signature: _____ Phone: _____ Fax: ____ Organization/Department: _____

Page 2 of 3 Last updated 6/2024



Legacy Day Treatment Unit Provider's Orders

Adult Ambulatory Infusion Order DENOSUMAB (Xgeva)

medical treatment of ______.

Thank you for your assistance.

Patien	t Name

Date of Birth:

Med. Rec. No (TVC MRN Only):

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

Dental Clearance Letter Re: _______ DOB:______ To Whom It May Concern:

It has been reported that a small number of patients taking these medications may develop a condition known as osteonecrosis following certain dental treatments. We are requesting a dental clearance prior to the initiation of the medical treatment. Please perform a complete dental evaluation and treat any dental conditions that may lead to future teeth extractions or other invasive dental procedures.

Our mutual patient noted above is scheduled to start denosumab or a bisphosphonate medication for the

Name of referring medical practitioner		
Date of last dental exam:		
Patient is free of active dental infection denosumab or a bisphosphonate med	on or need for further dental treatments dication	s and is cleared to receive
Patient is NOT cleared to receive der	nosumab or a bisphosphonate medica	tion
Additional comments:		
Printed name of Dentist	Signature of Dentist	Date

Page 3 of 3 Last updated 6/2024

Please fill out and fax this letter to the infusion center where patient will receive treatment. Attn: Pharmacist